Head-to-head · WeighScore
Freya Meds vs NowPatient
The verdict
NowPatient takes it — 65.5/100 to 58.6/100.
NowPatient grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NowPatient is a US-UK telehealth platform offering brand-name GLP-1 weight management access including Mounjaro, Wegovy (injection and oral tablet), and Saxenda.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Freya Meds | NowPatient |
|---|---|---|
| WeighScore | 58.6/100 | 65.5/100 |
| Grade | C | C |
| Scorecard rank | #365 | #217 |
| Semaglutide | $297/mo (compounded) | $1,349/mo (brand Wegovy) |
| Tirzepatide | $390/mo (compounded) | $1,069/mo (brand Mounjaro, promotional rate) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Yes |
Graded #365 · C
Strengths
- GLP-1 specialist — not a multi-category telehealth
- Price includes unlimited doctor consultations, monthly group calls, and a dietitian consultation
- Both semaglutide and tirzepatide available
- Multi-month discount on quarterly billing
- Claims 450,000+ enrolled
Where it loses points
- No visible LegitScript or PCAB accreditation
- Above-average pricing ($250–$390/mo)
- Compounded only — no brand-name options
- Now serves 49 U.S. states (one state excluded; specific exclusion not named)
Graded #217 · C
Strengths
- Free telehealth consultation — you only pay for the medication
- Brand-name Mounjaro, Wegovy injection, Wegovy oral tablet, and Saxenda all available
- One of the few platforms offering Wegovy in both injection and oral pill form
- No compounded options — every drug is FDA-approved brand-name
Where it loses points
- Cash-pay pricing tracks full brand list price (~$1,000–$1,350/mo)
- No compounded semaglutide or tirzepatide (usually the cheaper route)
- State availability determined during intake, not shown upfront
- Does not offer Foundayo (orforglipron)
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.